All In Biotech

Drug Trial Radar · NCT05144256

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

49

Actual

Start

Jun 8, 2022

Primary completion

May 3, 2024

Study completion Jun 2029

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years) and splenectomy status. Participants will be dosed by age and weight during a double-blind period consisting of an 8-week dose titration period followed by a 24-week fixed-dose period. Participants who complete the double-blind period will be eligible to receive mitapivat in the open-label extension (OLE) period.

Conditions

  • Pediatric Pyruvate Kinase Deficiency
  • Pediatric Hemolytic Anemia

Interventions

  • MitapivatDrug

    Tablets or granules

  • Mitapivat-matching placeboDrug

    Tablets or granules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Transfusion Reduction Response (TRR)Time frame: Week 9 to Week 32

Locations

22 sites in 10 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Stanford Medicine

    Palo Alto, California

  • Children's Healthcare of Atlanta - Emory

    Atlanta, Georgia

  • Boston Children's Hospital

    Boston, Massachusetts

  • Cure 4 the Kids Foundation, A Division of Roseman University of Health Sciences

    Las Vegas, Nevada

  • Weill Cornell Medical College

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Comprehensive Hemophilia Care Clinic at CHEO (Children's Hospital Eastern Ontario)

    Ottawa, Ontario, Canada

  • Fakultní Nemocnice Olomouc

    Olomouc, Czechia

  • Rigshospitalet

    Copenhagen, Denmark

  • Aarhus University Hospital

    Aarhus, Central Jutland, Denmark

  • Charite - UB - CVK - Medizinische Klinik

    Berlin, Germany

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinico Universitario Virgen de la Arrixaca

    Madrid, Spain

  • CHUV University Hospital of Lausanne

    Lausanne, Canton of Bern, Switzerland

  • Hacettepe University

    Ankara, Turkey (Türkiye)

  • İstanbul Üniversitesi Tıp Fakültesi [Istanbul University Faculty of Medicine] Çocuk Sağlığı Enstitüsü [Institute of Child Health]

    Istanbul, Turkey (Türkiye)

  • Ege University Faculty of Medicine

    Izmir, Adana, Turkey (Türkiye)

  • King's College Hospital NHS

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.